Sensorion gains more than 8% in Paris after Stifel reiterated its buy recommendation on Tuesday, with a target price of 1.50 euros, saying it was more optimistic about the chances of success for its drug candidate SENS-501.

Looking back on the recent American Society of Gene and Cell Therapy (ASGCT) conference, the research department believes that the data presented by other laboratories (Regeneron, Refreshgene) on this occasion proved rather encouraging.

The clinical results of competitors continue to pile up, and while we are eager to discover Sensorion's initial conclusions, the arrival of favorable data and the fact that the drug candidates are close together make us confident", say Stifel's analysts.

SENS-501 is a gene therapy program developed with a view to restoring hearing in patients carrying mutations linked to otoferlin deficiency.

In view of this information, Stifel says it has raised its chances of success for the product from 25% to 35%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.